EGFR and breast carcinoma: Gefitinib successfully inhibited EGFR activation in SK-Br-3, MDA-MB-261, and MDA-MB-468 breast cancer cells, although p42/p44-MAPK and AKT phosphorylation was not reduced in MDA-MB-468 compared to the other cells [123].